INSPRA

Compare INSPRA  to:
Compare
Compare

Generic Name for INSPRA

Eplerenone 25mg, 50mg; tabs.

Legal Classification:

Rx

Pharmacological Class for INSPRA

Aldosterone receptor blocker (mineralocorticoid-selective).

Manufacturer of INSPRA

Pfizer Labs

Indications for INSPRA

Hypertension.

Adult dose for INSPRA

Initially 50mg once daily; may increase after 4 weeks to max 50mg twice daily. Concomitant weak CYP3A4 inhibitors (eg, erythromycin, verapamil, saquinavir, fluconazole): initially 25mg once daily. Adjust based on serum K+ (see literature).

Children's dosing for INSPRA

Not recommended.

Contraindications for INSPRA

Hyperkalemia (serum K+ >5.5mEq/L) at initiation, severe renal impairment (CrCl ≤30mL/min), or concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). Type 2 diabetes with microalbuminuria, CrCl<50mL/min, serum creatinine >2mg/dL (males), >1.8mg/dL (females), or concomitant K+ supplements or K+ sparing diuretics.

Precautions for INSPRA

Severe hepatic impairment. Renal dysfunction. Monitor serum K+ at baseline, within 1st week, at 1 month after starting and after dose adjustment, then periodically. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for INSPRA

CYP3A4 inhibitors (see Contraindications and Dose). NSAIDs may antagonize antihypertensive effects. Angiotensin II receptor blockers, ACEIs increase hyperkalemia risk. Monitor lithium.

Adverse Reactions for INSPRA

Hyperkalemia, dizziness, GI upset, abdominal pain, cough, flu-like symptoms, albuminuria; increased serum creatinine, triglycerides, cholesterol; decreased serum sodium; rare: sex hormone related effects, increased BUN, uric acid, liver enzymes.

How is INSPRA supplied?

Tabs—30, 90

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.